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Uterine Papillary Serous Carcinoma (UPSC) is uncommon and accounts for less than 33 
5% of all uterine cancers. Therefore the majority of evidence about the benefits of 34 
adjuvant treatment comes from retrospective case series. We conducted a prospective 35 
multi-centre non-randomized phase 2 clinical trial using four cycles of adjuvant 36 
paclitaxel plus carboplatin chemotherapy followed by pelvic radiotherapy, in order to 37 
evaluate the tolerability and safety of this approach. 38 
 39 
Methods 40 
This trial enrolled patients with newly diagnosed, previously untreated patients with 41 
stage 1b-4 (FIGO-1988) UPSC with a serous-papillary component of at least 30%. 42 
Paclitaxel (175 mg/m2) and carboplatin (AUC 6) were administered on day 1 of each 43 
3-week cycle for 4 cycles. Chemotherapy was followed by external beam 44 
radiotherapy to the whole pelvis (50.4 Gy over 5.5 weeks). Completion and toxicity of 45 
treatment (Common Toxicity Criteria, CTC) and quality of life measures were the 46 
primary outcome indicators.  47 
 48 
Results 49 
Twenty-nine of 31 patients completed treatment as planned. Dose reduction was 50 
needed in 9 patients (29%), treatment delay in 7 (23%), and treatment cessation in 2 51 
patients (6.5%). Hematologic toxicity, grade 3 or 4 occurred in 19% (6/31) of 52 
patients. Patients’ self-reported quality of life remained stable throughout treatment. 53 
Thirteen of the 29 patients with stage 1-3 disease (44.8%) recurred (average follow-up 54 
28.1 months, range 8-60 months). 55 
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 56 
Conclusion 57 
This multimodal treatment is feasible, safe and tolerated reasonably well and would 58 
be suitable for use in multi-institutional prospective randomized clinical trials 59 
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Introduction 65 
Uterine papillary serous carcinoma (UPSC) is an aggressive histological subtype of 66 
endometrial cancer, accounting for less than 5% of its incidence, but 40% of its 67 
mortality [1]. Compared to those with endometrioid endometrial cancers, women with 68 
UPSC are more often non-obese, parous and older [2, 3].  69 
UPSC has a higher propensity for lymphovascular space invasion (LVSI), and 70 
intraperitoneal as well as extra-abdominal spread, than other endometrioid cancers [4-71 
9]. Depth of myometrial invasion does not correlate with the likelihood of 72 
extrauterine disease and approximately two-thirds of women with UPSC have disease 73 
outside of the uterus at diagnosis [4, 9]. 74 
Recurrence and mortality rates are high for all stages of this disease. Even for stage 1 75 
UPSC, the survival probability at 5 years is only 72% [10]. Established prognostic 76 
factors include lymph node involvement, LVSI and deep myometrial invasion [4, 11].  77 
Given the poor prognosis, most clinicians argue for adjuvant treatment for early-78 
stages of UPSC, but there is no standardized post-operative treatment. Because of its 79 
rarity, the majority of evidence is derived from retrospective studies. Few prospective 80 
(non-randomized) phase II trials have been reported to date [12, 13], suggesting that a 81 
combination of adjuvant chemotherapy and radiotherapy may improve survival in this 82 
patient group.  83 
Therefore, we conducted this prospective, multi-centre, non-randomized phase II 84 
clinical trial of a triple treatment regimen consisting of radical pelvic surgery, 85 
followed by systemic combination chemotherapy with carboplatin plus paclitaxel plus 86 
sequential radical pelvic radiotherapy. The primary objective was to assess the safety 87 
and feasibility of delivering that regimen. Secondary objectives were to assess the 88 
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patterns of disease recurrence, the impact of the treatment on patient quality of life 89 
(QoL) and overall survival, and to compare survival of pts on trial with a historical 90 
control group. 91 
Patients and Methods 92 
Study Setting 93 
This trial was conducted at four tertiary referral sites for gynaecological cancer in 94 
Australia and New Zealand. The study was approved by the Human Research Ethics 95 
Committee at all participating hospitals. Written informed consent was obtained from 96 
patients prior to the commencement of any study-related procedure.  97 
Patients were screened for eligibility after surgery when histopathological results were 98 
available. The inclusion and exclusion criteria are illustrated in Table 1. The trial was 99 
registered with the Protocol Registration System of the National Institutes of Health 100 
and the Therapeutic Goods Administration (TGA) under the Clinical Trial 101 
Notification Scheme (CTN) (Protocol Number: 2003/200, Trial Number: 2004/531).  102 
 103 
Treatment  104 
Standard surgical treatment consisted of at least total hysterectomy to confirm the 105 
histological diagnosis of UPSC. Treatment also included bilateral salpingo-106 
oophorectomy, bilateral pelvic and aortic lymph node dissection (at the discretion of 107 
the treating surgeon), omentectomy, and peritoneal cytology for apparent early 108 
disease (FIGO stages 1 or 2) or surgical cytoreduction of macroscopic tumor for 109 
advanced stages of disease (FIGO stages 3 and 4).  110 
Chemotherapy commenced at the clinicians’ discretion but generally 2-4 weeks 111 
postoperatively depending on patient’s surgical recovery. All patients received four 112 
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cycles of i.v. chemotherapy every 3 weeks. Paclitaxel 175mg/m2 and carboplatin (at a 113 
dose of AUC 6) were administered on the first day of each cycle. After the fourth 114 
cycle patients with stage 4 disease were to continue with chemotherapy to a total of 6 115 
cycles. Pelvic radiotherapy was given only to patients with stage 1 to 3 disease, and 116 
commenced after hematological count recovery from the last cycle of chemotherapy 117 
(usually 4-6 weeks after chemotherapy). Pelvic radiotherapy was administered at a 118 
dose of 50.4 Gy in 28 fractions over 5.5 weeks (1.8 Gy per fraction) for five days per 119 
week using a four field technique. If aortic nodal metastases were confirmed, patients 120 
also received aortic-field radiotherapy (45Gy -50.4 Gy in 25 - 28 fractions) depending 121 
on the site and volume of nodes and patient’s tolerance. Because of increased risks of 122 
hematologic toxicity, concurrent chemotherapy (as radio-sensitizer) was avoided. 123 
Vaginal vault brachytherapy boost was allowed at clinicians’ discretion following 124 
pelvic radiotherapy. 125 
Evaluation of patients including quality of life assessment 126 
At trial entry (post-surgery) all patients had full blood count, biochemistry, liver 127 
functions tests and CA125, a chest x-ray and ECG. A baseline CT of chest to pelvis 128 
was to be performed for all patients thought to have any type of residual disease, and 129 
repeated after 3 and 6 cycles of chemotherapy if residual disease was suspected. 130 
Blood counts were repeated prior to each cycle of chemotherapy and prior to start of 131 
radiotherapy. Toxicity was evaluated according to the National Cancer Institute 132 
Common Terminology Criteria (CTC) for Adverse Events (AE), version 3.0 prior to 133 
each cycle of chemotherapy and weekly during radiotherapy. Patients were followed-134 
up clinically at three month intervals. Recurrence of tumor was confirmed 135 
histologically whenever possible and or by radiological imaging. 136 
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Three different reliable and validated scales were used to assess quality of life (QoL) 137 
outcomes prior to each cycle of chemotherapy, and at the start and end of 138 
radiotherapy. The Hospital Anxiety and Depression Scale’s (HADS) anxiety and 139 
depression subscale scores varied from 0-21. HADS scores between 0-7 were classed 140 
as ‘normal’, 8-10 as ‘doubtful cases’, and 11 or higher as ‘likely anxiety/depression 141 
cases’ [14]. The Center for Epidemiologic Studies Depression Scale (CES-D) scores 142 
(which range from 0-60) of 16 or higher were considered indicative of depression 143 
[15]. The Functional Assessment of Cancer Therapy (FACT-G) accompanied by a 144 
disease specific endometrial cancer subscale (FACT-en) was used to assess patient’s 145 
global and disease-related QoL. FACT-G provides a maximum score of 108 when all 146 
the four subscales are combined: 0-28 for each of physical, social and functional well-147 
being and, 0-24 for emotional well-being [16]. FACT-en scores could vary from 0 to 148 
64. The treatment outcome index (TOI) was calculated by adding up the physical, 149 
functional and endometrial subscales (possible range: 0-120). Higher scores on all 150 
subscales indicate better QoL  [17].  151 
Statistical analysis 152 
A pragmatic sample size of 30 patients was chosen based on predicted recruitment 153 
within the participating centers. The regimen was considered feasible and tolerable if 154 
80% of patients could complete the planned treatment without requiring treatment 155 
cessation. . Morbidity and QoL analyses were performed for all recruited patients 156 
(n=31).  157 
Adverse events: Adverse events (AE) were classified and graded by CTC categories, 158 
and collapsed into ‘low’ grade (grades 1 and 2) and ‘high’ grade (grades 3 and or 4). 159 
Descriptive statistics were used to present the number of patients and percent of 160 
patients by AE categories and grade.  161 
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Quality of Life: Descriptive statistics were used to summarize patients’ QoL scores 162 
over time and unadjusted results are presented. A change of 2 points in the QoL 163 
scores was considered clinically significant for the FACT-G subscales, 4 points for 164 
the FACT-en subscale and 5 points for the FACT-G summary score and TOI, and a 165 
change of one third of a standard deviation was defined as clinically significant for 166 
HADS and CES-D [18-21]. Linear mixed models were used to evaluate changes in 167 
QoL over time. 168 
Survival: Overall survival (OS) was calculated from date of surgery to date of death 169 
or date of last follow-up if censored. The Kaplan Meier method was used to compare 170 
survival among patients with stage 1b to stage 3 in this study (n=29) with those of 171 
matched historical controls.  172 
Historical Controls: Thirty-seven patients who received treatment for UPSC at the 173 
Queensland Centre for Gynaecological Cancer between September 1999 and August 174 
2004 represented the historical controls. They were selected on the basis of stage (1b 175 
to 3c) (FIGO 1988) and age (age <80 years at the time of diagnosis). Patients received 176 
a variety of postoperative treatment regimens. Seven patients received chemotherapy 177 
only, 3 patients received external beam radiotherapy only and 5 patients were treated 178 
with a combination of chemo and external beam radiotherapy. The remainder either 179 
received no treatment after surgical staging (n=10), brachytherapy only (n=4) or other 180 
combinations of treatment alternatives (n=8)[radiotherapy and brachytherapy (n=3), 181 
chemo- and brachytherapy (n=1), chemo-, radio- and brachytherapy (n=1), hormone 182 
replacement therapy only (n=1), chemo- and radiotherapy in combination with 183 
hormone replacement therapy (n=1), or chemo-, radio- and brachytherapy in 184 
combination with hormone replacement therapy (n=1)].  185 
 186 
  9 
Results 187 
Patient characteristics  188 
Thirty-one patients from four participating institutions in Australia and New Zealand 189 
were registered between September 2004 and February 2008. Patients’ median age 190 
was 63 years (range 37-77). Twenty-seven patients (93%) had ECOG status zero or 191 
one; two patients (7%) had ECOG status 2. Twelve patients (41%)  had tumors that 192 
invaded the Lympho Vascular Space (LVSI+).  193 
One patient with UPSC confined to the endometrium but with extensive LVSI (non-194 
invasive) throughout the myometrium, who had to be regarded as stage 1A according 195 
to the FIGO 1988 staging classification was registered and treated. The distribution of 196 
FIGO (1988) stages is shown in Table 2. 197 
Treatment received 198 
Twenty nine out of the 31 patients enrolled, completed their treatment (93.5% 199 
completion rate, 95% CI: 80.9%-98.6%). Of the 29 patients with stages 1-3C who 200 
were planned to receive chemotherapy plus sequential radiotherapy, two patients 201 
(6.9%) received only two cycles of chemotherapy due to toxicity (grade 3 peripheral 202 
neuropathy and depression (n=1); grade 3 neutropenia (n=1)). All 29 patients received 203 
pelvic radiotherapy as planned, and eight patients (27.6%) also had a vaginal vault 204 
brachytherapy boost to the top 3 cm of the vagina. The two patients with stage 4 205 
disease completed all 6 cycles of planned chemotherapy. Chemotherapy dose 206 
reduction was needed in 9 (29%), treatment delay in 7 (23%), and treatment cessation 207 
in 2 patients (6.5%). Radiotherapy was delivered as planned for all patients.  208 
 209 
Toxicity  210 
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All patients had at least one grade 1 or 2 adverse event (AE), with 15 patients (48%) 211 
experiencing at least one high grade (3 or 4) AE (Table 3). AEs were related more 212 
commonly to the gastrointestinal system (e.g., nausea, vomiting), closely followed by 213 
pain (e.g., myalgia), neurological issues (e.g., peripheral neuropathy) and 214 
constitutional symptoms (e.g., fatigue). Fourteen patients (45%) experienced at least 215 
one high grade, non-hematologic toxicity and six patients (19%) experienced at least 216 
one, high-grade, hematologic toxicity. Five of the six patients who experienced high 217 
grade hematologic toxicity also experienced high grade non-hematologic toxicity. 218 
Peripheral neuropathy (grades 3 and 4) was noticed in 2 patients (6%). Five patients 219 
(16%) experienced grade 3 or 4 neutropenia with two patients (6%) exhibiting febrile 220 
neutropenia. Toxicities were appropriately managed and no treatment-related deaths 221 
occurred. 222 
Quality of life 223 
Overall, patients’ QoL remained largely stable over the course of the treatment (Table 224 
4). Compared to the baseline assessment after surgery, scores for anxiety (HADS, 225 
anxiety) and depression (HADS, depression and CES-D) improved after the first cycle 226 
of chemotherapy, worsened slightly at the commencement of radiotherapy and 227 
subsequently improved again. FACT-G scores remained largely unchanged between 228 
commencement and completion of treatment. The FACT-en and TOI scores showed a 229 
small, decline in QoL throughout the treatment period, but these changes did not 230 
reach clinical significance. Most of the QoL variables showed non-linear or no clear 231 
trend over the specified time points with the exception of Endometrial Wellbeing 232 
(EnWB) which showed a linear downward trend (P<0.05). 233 
Recurrence and Survival  234 
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After a median follow-up of 28.1 months (range 8-60 months), thirteen of the 29 235 
patients with stage 1-3 disease (44.8%) recurred. The site of recurrence was pelvis 236 
(n=2), abdomen (n=2), distant (n=5) or multiple sites (n=4). Nine (31%) patients died 237 
due to progressive disease (n=8) or unknown cause (n=1). The two patients with stage 238 
4 disease relapsed at multiple sites. 239 
Characteristics of patients that recurred are illustrated in Table 5. Disease recurrence 240 
was seen in 3 of the 10 stage 1 patients (30%), 2 of the 5 stage 2 (40%) and 8 of the 241 
14 stage 3 (57%) patients. Overall survival probability was 77.4% at two years. The 242 
two-year survival probability was 85.6% for stage 1 or 2 patients and 68.8% for stage 243 
3 patients. 244 
Historical Controls  245 
Distribution of stages of patients in the historical controls is illustrated in Table 2. 246 
Patients within the historical cohort were older on average and included a higher 247 
proportion of patients with earlier stage of disease compared to the trial cohort. Their 248 
median follow-up was 40.9 months (range: 2.8-114.7 months) and overall survival 249 
probability was 75.7% at two years. Kaplan-Meier curves comparing overall survival 250 
of patients in this study with that of the historical controls is shown in Figure 1.  251 
 252 
Discussion 253 
This non-randomized Phase II clinical trial evaluated the tolerability and safety of 254 
four cycles of carboplatin and paclitaxel combination chemotherapy plus sequential 255 
pelvic radiotherapy in the postoperative setting for patients with UPSC. This 256 
treatment regimen was generally well-tolerated with 29 of 31 patients (93.5%) 257 
completing treatment as scheduled.  258 
  12 
Survival of patients with stage 1 and 2 UPSC without adequate staging and / or 259 
adjuvant treatment is poor. From early retrospective data it became clear that 260 
meticulous surgical staging provides useful information on the extent of disease, thus 261 
impacting on the postoperative treatment plan in patients with early stage UPSC. 262 
However, generating evidence on treatment of UPSC is challenging due to low 263 
incidence rates resulting in few prospective trials. Several groups have presented 264 
retrospective data on the outcomes of treatment with the inevitable inherent selection 265 
bias [22]. The interpretation of these retrospective studies is controversial because of 266 
the use of multiple adjuvant treatment regimens and heterogeneous patient groups 267 
probably similar to our historical control group. Some publications favor radiotherapy 268 
while others recommend chemotherapy or a combination of both in patients with 269 
UPSC [3, 23, 24]. 270 
The role of whole abdominal radiotherapy (WART) was evaluated in GOG 94 [25]. 271 
This study enrolled 21 patients with clinical stage 1 or 2 UPSC. Patients had radical 272 
surgery followed by (WART) with a pelvic boost. Five year progression free survival 273 
was 38%. The majority of treatment failures were within the radiation field, which led 274 
to the conclusion that a combination of chemotherapy and radiotherapy may improve 275 
survival outcomes. However, the combination of systemic chemotherapy and pelvic 276 
radiotherapy, its tolerability and safety profile in the setting of previous radical pelvic 277 
surgery had not been examined prior to the time of the writing of this study protocol.  278 
In our study, non-hematologic toxicity grade 3 or 4 was recorded in 45% of patients, 279 
and hematologic toxicity grade 3 or 4 was documented in 19%. No case of radiation-280 
associated fistula or bowel obstruction requiring intervention was recorded. All but 281 
two patients completed the treatment according to the study protocol. The prospective 282 
  13 
clinical trial by Fields and colleagues [12] evaluated pelvic radiation treatment 283 
‘sandwiched’ between six cycles of paclitaxel/platinum chemotherapy in 30 patients 284 
with stage 1 to 4 UPSC and found similar outcomes. All but one patient completed 285 
treatment as per protocol. Of 177 chemotherapy cycles administered they observed 286 
grade 3 or 4 neutropenia, thrombocytopenia and anemia in 42%, 3% and 1%, 287 
respectively [12]. Distribution of chemotherapy toxicity was similar in cycles of 288 
chemotherapy given before and after radiotherapy. In comparison, the Hoosier 289 
Oncology Group reported outcomes of a phase 2 study on 21 patients with stage 1 and 290 
2 UPSC. Patients received intraperitoneal radioactive phosphorus and vaginal 291 
brachytherapy to the whole vagina. The treatment was extremely well tolerated, with 292 
minimal low-grade toxicity and no grade 2, 3 or 4 toxicities [13]. Two of these three 293 
studies used radiotherapy to the whole pelvis and it seems that hematologic and non-294 
hematologic toxicity was distinctly more common and severe in those studies [12, 295 
25]. Therefore, it seems that the external beam radiotherapy component may account 296 
for a large part of the incidence and severity of toxicity observed in our trial.  297 
The sample size of this phase II trial did not allow for extensive statistical analysis of 298 
QoL data. Patients’ QoL remained acceptable throughout treatment.  These QoL 299 
outcomes are consistent with the encouraging toxicity outcomes and support the use 300 
of this treatment combination. Unfortunately, none of the previous prospective 301 
clinical trials on UPSC has QoL available for comparison. However, in a published 302 
review, while gynecological cancer patients appear to have worse QoL during 303 
treatment compared to for example breast cancer patients, the majority seem to cope 304 
well with treatment and return to QoL comparable to norms shortly after cessation of 305 
treatment [26]. Carter et al studied gynecological cancer patients undergoing intensive 306 
chemotherapy and found little difference in QoL across cycles [27].  In contrast, 307 
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Lutgendorf et al described lower physical, emotional and functional wellbeing, but no 308 
difference in anxiety and depression between more extensively treated gynecological 309 
cancer patients or those receiving surgery only [28].  310 
The two year survival probabilities of 85.6% for patients with stage 1 or 2 disease and 311 
68.8% for patients with stage 3 disease, is comparable to previous prospective studies. 312 
After a median follow up of 28.1 months, thirteen of the 29 patients with stage 1-3 313 
(44.8%) disease experienced recurrence with the majority of recurrences occurring 314 
outside the pelvis. Fields et al. reporting on radiation “sandwiched” between 315 
combination chemotherapy reported an overall survival of 75% for patients for stage 1 316 
and 2 UPSC and 52% for advanced disease (stages 3 and 4) at two years [12]. The 317 
Hoosier Oncology Group evaluating intraperitoneal phosphorus plus vaginal 318 
brachytherapy reported an overall two-year survival 93.3% (n=17) for patients with 319 
stage 1 or 2 UPSC [13]. Survival in the GOG 94 study after WART was poor [25].  320 
We compared overall survival of our study group with historical controls from a three 321 
year time period immediately prior to this trial. The number of patients available for 322 
analysis was similar for both the time periods but patients in the historical control 323 
group were older and more likely to be diagnosed with stage 1 disease. Even though 324 
such an imbalance should favor outcomes for historical controls, when compared to 325 
those who participated in this study, the survival outcomes were similar (Figure 1). It 326 
should also be noted that not all the patients in this trial underwent surgical staging 327 
and patients may have been assigned a stage lower than their actual stage.   328 
Recently, a consortium of 10 gynecologic oncology units presented a retrospective 329 
analysis of data on 55 patients with stage 2 UPSC [29]. Patients who received 330 
chemotherapy ± radiotherapy (CT±RT) had a longer progression free survival and a 331 
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lower risk of recurrence (11%) than the radiotherapy (RT) alone group (50%). Of the 332 
19 patients in the CT±RT group, all patients had platinum/taxane combination 333 
chemotherapy and 12 of the 19 patients had radiotherapy. The same group has more 334 
recently published similar results for a cohort of stage 1 patients, suggesting a survival 335 
benefit and lower relapse rate in patients treated with platinum-taxane based 336 
chemotherapy [29]. However, another recently published retrospective series of 58 337 
stage 1 and IIA UPSC patients showed no significant difference in overall survival 338 
between those patients who received carboplatin and paclitaxel chemotherapy and 339 
those that did not. In contrast, a survival benefit was suggested for those patients who 340 
received adjuvant radiation [30]. Unfortunately the selection bias inherent in these 341 
retrospective studies is a major confounder and only a randomized controlled trial will 342 
be able to report on treatment efficacy. 343 
In summary, our data support the feasibility and safety of multimodal therapy as an 344 
emerging treatment concept for UPSC. Triple treatment consisting of surgery, 345 
chemotherapy and radiotherapycan be offered to patients less than 80 years of age, 346 
with histologically confirmed and myoinvasive UPSC. Patients with other high-risk 347 
uterine cancers, such as clear cell cancers or malignant mixed mullerian tumours may 348 
also benefit from this treatment regimen. Nevertheless, the generally poor results that 349 
are seen in patients with UPSC and the conflicting data from the available literature, 350 
mandate the need for international collaboration in order to perform prospective 351 
randomized trials incorporating novel therapeutic approaches to improve patient 352 
outcomes. 353 
354 
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Table 1: Inclusion and exclusion criteria for eligibility in study 
Inclusion criteria: 
- Histologically confirmed primary diagnosis of UPSC (serous-papillary component of ≥ 30% on a 
hysterectomy specimen) 
- Stage 1b-4 disease  
- Chemonaive for UPSC  
- Females between 18-80 years of age 
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 
- Adequate bone marrow, renal, hepatic and neurologic function (ANC ≥ 1,500/ul, Platelets ≥ 
100,000/ul, Creatinine ≤ 1.5 x ULN, Bilirubin ≤ 1.5 x ULN, Neuropathy ≤ CTC Grade 1) 
- Written informed consent 
Exclusion criteria: 
- Presence of other histological type than UPSC or endometrioid 
- Personal history of malignancy and disease-free for less than 5 years 
- Uncontrolled hypertension (>180mmHg/100mmHg), cardiac arrhythmia or diabetes mellitus 
- History of another malignancy within the last 5 years that could affect the diagnosis or assessment 
of UPSC 
- Estimated life expectancy of less than 6 months 
- History of serious cardiac disease within the last 6 months 
- Active serious infection or underlying medical condition impairing protocol treatment 
- Medical or psychiatric illness, dementia or altered mental status impairing informed consent 
- History of severe allergic reactions to drugs containing cremophor or hypersensitivity to 
paclitaxel, carboplatin or cremophor EL 
- Previous radiotherapy to the whole pelvis 
- Uncontrolled pelvic inflammatory disease contraindicating pelvic radiotherapy 
- Breast-feeding 






Table 2: Patient and Disease Characteristics of patients enrolled in our study and of the 
historical control at baseline 
 
Characteristic All patients (this study)  
    N                                 % 
Historical control 
    N                                 % 
Age at baseline in years, median (range)  63 (37-77) 68 (41-80) 
Total           31                    100          37                   100 
Prognostic factors at baseline   
Stage   
1a 1 3.3 0 0 
1b 4 12.9 13 35.1 
1c 5 16.1 6 16.2 
2a 1 3.3 3 8.1 
2b 4 12.9 1 2.7 
3a-c 14 45.1 14 37.8 





Table 3. Summary of adverse events for 31eligible patients by CTC category (v. 3.0) and 
grade 
 
  CTC grades (Patients)   
Categories 1 and 2 % 3 and 4  % Total   % 
Allergy/Immunology 1 3.2% 0 0.0% 1 3.2% 
Blood/Bone marrow 23 74.2% 6 19.4% 23 74.2% 
Cardiac general 1 3.2% 2 6.5% 3 9.7% 
Constitutional symptoms 24 77.4% 4 12.9% 24 77.4% 
Dermatology/Skin 22 71.0% 0 0.0% 22 71.0% 
Gastrointestinal 30 96.8% 2 6.5% 30 96.8% 
Hemorrhage/Bleeding 4 12.9% 0 0.0% 4 12.9% 
Infection 5 16.1% 0 0.0% 5 16.1% 
Lymphatics 6 19.4% 2 6.5% 8 25.8% 
Metabolic/Laboratory 3 9.7% 4 12.9% 6 19.4% 
Musculoskeletal/Soft tissue 2 6.5% 0 0.0% 2 6.5% 
Neurology 23 74.2% 2 6.5% 25 80.6% 
Pain 29 93.5% 4 12.9% 29 93.5% 
Pulmonary/Upper respiratory 5 16.1% 0 0.0% 5 16.1% 
Renal/Genitourinary 2 6.5% 0 0.0% 2 6.5% 
Sexual/Reproductive function 1 3.2% 0 0.0% 1 3.2% 
Syndromes 2 6.5% 0 0.0% 2 6.5% 
Vascular 1 3.2% 2 6.5% 3 9.7% 





Table 4: Quality of life outcomes for each treatment time point (n=31 patients) 
 
* higher scores indicate greater symptoms 
** higher scores indicate better quality of life  
 
Scale, Mean (SD) Chemotherapy Radiotherapy 
 Cycle 1 Cycle 2 Cycle 3 Cycle 4 Start End 
HADS, anxiety* 5.71 (3.02) 3.88 (3.24) 3.12 (2.58) 3.54 (3.35) 3.85 (2.90) 2.96 (2.80) 
No. patients 28 26 25 26 26 25 
HADS, depression* 2.25 (3.00) 2.35 (2.46) 2.04 (2.28) 2.12 (2.69) 2.46 (3.10) 2.76 (3.53) 
No. patients 28 26 25 26 26 25 
CES-D* 12.32 (6.14) 10.74 (9.24) 11.76 (8.26) 8.29 (6.69) 8.96 (7.60) 7.48 (8.52) 
No. patients 25 23 25 28 25 25 
FACT-G** 91.08 (13.69) 92.56 (13.95) 93.01 (10.60) 92.59 (14.24) 92.07 (13.24) 91.28 (16.03) 
No. patients 28 26 25 26 24 25 
FACT-en** 59.21 (4.61) 57.08 (6.29) 57.52 (5.51) 57.49 (6.27) 57.99 (4.93) 56.08 (6.81) 
No. patients 29 26 26 25 26 25 
FACT-all** 149.08 (17.49) 149.61 (18.82) 150.31 (15.35) 148.38 (19.35) 149.73 (17.28) 147.36 (21.47) 
No. patients 29 26 25 23 24 25 
TOI** 105.07 (12.14) 103.47 (15.91) 103.43 (12.98) 102.40 (16.92) 103.43 (13.34) 100.32 (17.51) 
No. patients 28 26 25 24 24 25 
 Table 5: Characteristics of patients who recurred (13/29 patients with disease stage 1-3) 
Patients with recurrence (n=13) 
Patient Age at 
diagno
sis 






201001 54 3A TAHBSO, washings, 
omentectomy 
4 X Carbo/Tax + 
EBRT  
6 Distant 8 
(died) 
301001 54 4B TAHBSO, bilateral 
Pel+PA LND, 
omentectomy, washings 





301002 71 1B TAHBSO, bilateral 
Pel+PA LND, 
omentectomy, washings 
4 X Carbo/Tax 
+EBRT+ VVBT 
23 Distant 28 
(died) 
401007 60 3C TAHBSO, bilateral 
Pel+PA LND, 
omentectomy, washings 
4 X Carbo/Tax + 
EBRT 
11 Abdomen 20 
(died) 
401008 62 2B TAHBSO, washings  4 X Carbo/Tax 
+EBRT+ VVBT 
12 Multiple 20 
(died) 
401011 68 3B TAHBSO, omentectomy 4 X Carbo/Tax + 
EBRT 
13 Distant 36 
(died) 
401012 63 3C TAHBSO, bilateral 
Pel+PA LND, 
omentectomy, washings 
4 X Carbo/Tax + 
EBRT 
16 Distant 21 
(died) 
401016 77 3C TAHBSO, bilateral 
Pel+PA LND, washings 
4 X Carbo/Tax + 
EBRT 
32 Distant 37 
401018 72 3A TAHBSO, bilateral 
Pel+PA LND, 
omentectomy, washings 






901001 65 1C TAHBSO, bilateral 
Pel+PA LND, washings 
4 X Carbo/Tax + 
EBRT 
15 Multiple 16 
(died) 
901002 77 1C TAHBSO, bilateral 
Pel+PA LND, washings 
4 X Carbo/Tax + 
EBRT 
33 Pelvis 40 
(died) 
901003 50 3C TAHBSO, bilateral 
Pel+PA LND, 
omentectomy, washings 
5 X Carbo/Tax + 
EBRT 
16 Pelvis 23 
901004 65 2B TAHBSO 4 X Carbo/Tax 
+EBRT+ VVBT 
17 Abdomen 26 
TAHBSO: Total Abdominal Hysterectomy and Bilateral Salpingo Oophorectomy; Pel+PA LND: Pelvic and Para-aortic 
Lymph Node Dissection; EBRT: External Beam Radiotherapy; VVBT: Vaginal Vault Brachytherapy; DFS: Disease-free 
Survival; FU: Follow-up 
 
Figure 1: Kaplan-Meier overall survival curves of patients in this UPSC trial (stages 1b-3C) 
compared with historical control (n=37)
Survival curve for historical control
+ Censored cases in each of the studies
Log-rank (Mantel-Cox) p-value: 0.463
-- Survival curve for patients in our study
